GLP-1 Pills Win on Convenience. Shots Still Lead on Weight Loss.
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Oral GLP-1s are selling fast enough that the two companies making them are arguing publicly about who's ahead. With headlines telling you how popular one choice is over the other it can feel confusing when deciding which is right for you: the pills are genuinely easier to live with, and the top injectable doses still produce more weight loss. Both are reasonable choices, and which one fits depends less on the drugs than on you. Both are always prescribed by a clinician who evaluates your health history when making a determination which is best.
Who This Helps
This is for you if you're choosing between a pill and an injection, or wondering whether to ask about switching. If the product names are a blur, our simple guide to the terms sorts them out first.
The market claims contradict each other, so treat them lightly
On September 14, 2026, Eli Lilly said it had captured more than 30% of new patients starting an oral obesity treatment in the US (Reuters). In August, Novo Nordisk's chief executive put his company's Wegovy pill at roughly 90% of the same market. Those two cannot both be right.
Independent prescription data sits lower than either. An analyst note in late August, drawing on IQVIA figures, put Foundayo at about 21.5% of new prescriptions in the oral obesity category (Fierce Pharma). Analysts also note that tracking may undercount prescriptions written through telehealth.
The honest summary is that oral options launched fast and are taking real share, and nobody outside these companies knows the precise split. None of that tells you which one to take, and popularity of the medication shouldn’t guide this choice.
Three oral options, and they are not interchangeable
- Foundayo (orforglipron), approved April 1, 2026. A small molecule rather than a peptide, which is why it survives digestion without changes to your routine. Lilly describes it as the only GLP-1 pill for weight loss "that can be taken any time of the day without restrictions on food and water intake" (Eli Lilly).
- The Wegovy Pill (oral semaglutide 25 mg), approved December 22, 2025. A peptide in tablet form, so it needs an absorption helper and strict timing.
- Rybelsus (oral semaglutide 3, 7 and 14 mg). Approved for type 2 diabetes, not for weight management. People mix this up constantly.
The timing rules on the semaglutide tablets are the part worth understanding before you choose one. The Rybelsus label says to take it on an empty stomach with up to 4 ounces of water, then wait at least 30 minutes before food, other drinks or other oral medicines (Rybelsus prescribing information). Skip the rules and you absorb less. That's a daily routine, every day, not an occasional inconvenience.
The weight loss numbers, side by side and with a caveat
Read these as a rough map since these aren’t guaranteed results. Every number comes from a different trial with different participants and different rules, and cross-trial comparison is not the same thing as a head-to-head.
- Foundayo, highest dose: 27.3 pounds, or 12.4%, against 2.2 pounds or 0.9% on placebo, among those who stayed on treatment (Eli Lilly). Counting everyone regardless of whether they continued, it was 11.1%.
- Wegovy Pill: 16.6% average weight loss when treatment was adhered to, with about one in three losing 20% or more.
- Wegovy injection, 2.4 mg: 14.9% over 68 weeks (New England Journal of Medicine).
- Wegovy HD injection, 7.2 mg: 18.7% over 72 weeks (Lancet Diabetes and Endocrinology).
- Zepbound injection, 15 mg: 20.9% over 72 weeks (New England Journal of Medicine).
Only one true head-to-head exists among these. SURMOUNT-5 compared tirzepatide with semaglutide by injection in 751 adults over 72 weeks and found 20.2% against 13.7%, though it was open-label, meaning everyone knew which drug they were getting (New England Journal of Medicine). No trial has compared Foundayo with any injectable.
Where a pill genuinely fits better
- You won't inject, or you'd rather not. Needle fear is common and a real barrier. For someone who will not start an injection, the comparison isn't pill versus shot. It's pill versus nothing.
- No refrigerator involved. Injectable pens need cold storage before use. Tablets don't, which matters for travel, for shift work, and for anyone with an unreliable fridge.
- Discretion and routine. A tablet in a pocket asks less of you than a pen, a sharps container and a weekly ritual.
- Foundayo specifically has no timing rules. Any time of day, with or without food. Among the orals, that's the one that asks least.
Where an injection still has the edge
- The top of the range. The highest injectable results run above what the orals have shown, and the only head-to-head was between two injectables.
- Once a week beats once a day. Fifty-two decisions a year instead of 365 - if you take a medication less often, there’s less chance to forget or mix up your timing. Evidence on dosing frequency and adherence comes mostly from other conditions, so treat this as reasoning rather than GLP-1 trial data.
- No fasting window. An injection doesn't care what you ate. For the semaglutide tablets, the empty-stomach rule is the daily cost.
- Absorption problems change the math. The label says oral semaglutide "is not recommended in patients with severe gastroparesis" (Rybelsus prescribing information). If your stomach doesn't empty reliably, a shot sidesteps the question.
What they share, and what it costs
Some things don't differ by format. All of these carry the same core contraindications, including a personal or family history of medullary thyroid carcinoma and MEN 2, and prior serious allergic reaction to the ingredient (Foundayo prescribing information). Stomach side effects are common across the class either way, and our piece on what week six actually looks like covers what's typical.
On price, as of September 2026 Novo Nordisk lists self-pay pricing for the Wegovy pill at $149 to $299 a month depending on dose, the standard injection pen at $349, and the higher-dose pen at $399 (NovoCare). Lilly lists Foundayo self-pay starting at $149 a month for the lowest dose (Eli Lilly). Check current prices directly, because these move, and Novo's page notes its pricing is set to change after December 31, 2026.
For Medicare, the Bridge demonstration covers Wegovy in all formulations, Foundayo, and Zepbound in the KwikPen only. The single-dose Zepbound pen and vials are not covered (CMS).
Final Takeaway
The arrival of workable pills is good news, and it isn't a replacement story. If the highest possible weight loss is the goal and injecting doesn't bother you, the injectables still sit at the top. If a needle is the thing standing between you and treatment, or a fridge is, or a weekly ritual you know you won't keep, then a pill that you'll actually take beats a shot that stays in the box. Bring the practical stuff to your prescriber, the parts about your routine and your travel and what you know about yourself, because that's the part the trial data can't answer for you.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Is the GLP-1 pill as good as the shot?
On average weight loss, the highest injectable doses have produced larger results than the oral options in their own trials. No trial has compared Foundayo directly with an injectable, so those are cross-trial comparisons rather than a head-to-head. For someone who will not use an injection, the pill is clearly the better option, because a medication you take beats one you don't.
Do I have to take a GLP-1 pill on an empty stomach?
It depends which one. The semaglutide tablets need an empty stomach, no more than 4 ounces of plain water, and a 30 minute wait before anything else. Foundayo has no food or water restrictions and can be taken any time of day.
Is Rybelsus a weight loss pill?
No. Rybelsus is oral semaglutide approved for type 2 diabetes. The semaglutide tablet approved for weight management is a different, higher strength product. They are easy to confuse and are not interchangeable.
Sources
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading
A study found 15 cases of a rare B1 deficiency brain injury in GLP-1 users. See what the data shows and the warning sign 13 of them had first.
AstraZeneca's elecoglipron, an experimental once-daily GLP-1 pill, is heading to Phase 3. See what the early results show and what is still unproven.
A plain-language side-by-side of Foundayo and the Wegovy pill. Dosing, weight loss, side effects, and cost compared for 2026.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.